论文部分内容阅读
据悉,生物医药“十三五”规划已基本制定完成,按照相关工作流程,这一规划将在今年下半年正式出台。根据规划,“十三五”期间我国生物医药产业将重点发展重大疾病化学药物、生物技术药物、新疫苗、新型细胞治疗制剂等多个创新药物品类,同时发展生物3D打印技术等重大医疗技术。根据规划,抗肿瘤、抗抑郁、糖尿病、肾病、心脑血管病等药物将是“十三五”期间重点发展的新药品类;在临床中有巨大应用前景的蛋白及多肽药物、新型细胞制剂等生物医药制剂也将得到优先发展;此外,生物3D打印、大分子药物、干细
It is reported that biomedicine “13th Five-Year Plan has been basically completed, according to the relevant workflow, this plan will be formally introduced in the second half of this year. According to the plan, during the ”13th Five-Year Plan“, China’s biopharmaceutical industry will focus on the development of a number of innovative pharmaceutical categories of major diseases such as chemical drugs, biotech drugs, new vaccines and new cell therapy preparations, as well as the development of major medical technologies such as bio-3D printing technology technology. According to the plan, drugs such as anti-tumor, antidepressant, diabetes, nephropathy and cardiovascular and cerebrovascular diseases will be the new drugs that will be mainly developed during the ”13th Five-Year Plan" period. Proteins and peptide drugs, which have great application prospect in the clinic, Biopharmaceutical preparations such as cell preparations will also be given priority; in addition, bio-3D printing, macromolecular drugs,